Developing new Treatments for Tourette Syndrome: Therapeutic Trials with Modulators of Glutamatergic Neurotransmission
Academy Sites Books Clinical CME E-mail Journals Links Medline Parents Pharmaceuticals Professional Research Teaching Web Portals Internet Course
This research is being done to determine whether glutamate altering drugs are effective at suppressing tics. Included in this double-blind, placebo-controlled 8 week study are both a glutamate agonist (D-serine) and riluzole (a glutamate antagonist). This study is approved by the FDA and the Johns Hopkins IRB. Individuals aged 8-17 years with moderate to moderate-severe Tourette syndrome or chronic motor/vocal tics (total tic score >22) may join. Participants would need to be available come to Baltimore every two weeks for eight weeks.
Handout for doctors
Handout for patients
Research Assistant: Christy Morris-Berry
This study is approved by the Johns Hopkins Institutional Review Board (NA_ 00023969).
Sponsored by the NIH.
Go back to Seeking Patients page
Last revised 11-Feb-2011 by Steven Leber